Updates in Follicular Lymphoma

Slides:



Advertisements
Similar presentations
Follicular Lymphoma Laurie H. Sehn, MDCM, MPH BC Cancer Agency Vancouver, Canada.
Advertisements

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.
Wilmot Cancer Institute University of Rochester Medical Center
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Consolidation treatment with Y 90 Ibritumomab Tiuxetan after R-CHOP induction in high-risk patients with Follicular Lymphoma (FL) (GOTEL-FL1LC): a multicentric,
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)
Dyer MJS et al. Proc ASH 2014;Abstract 1743.
What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,
ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.
Low Grade Lymphomas: Treatment approaches Parameswaran Venugopal, MD Professor of Medicine Rush University Medical Center.
GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma New Findings in Hematology: Independent Conference.
Campos M et al. Proc EHA 2013;Abstract B2009.
Campos M et al. Proc EHA 2013;Abstract B2009.
A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy plus Rituximab vs CHOP Chemotherapy plus Iodine-131-Tositumomab for the Treatment.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Innovations and Issues in Mantle Cell Lymphoma
Relapsed/Refractory Follicular Lymphoma Conundrums
Updates in Hodgkin Lymphoma
Peripheral T-Cell Lymphoma in 2013
Prolonging Progression-Free Survival in Follicular Lymphoma
Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.
Goals of Therapy in Relapsed CLL
Advances in Lymphoma.
R-CHOP Stem Cell Transplantation for Follicular Lymphoma
Novel and Emerging Approaches to Treating CLL
Activity Goals. Activity Goals Case Presentation.
Jonathan W. Friedberg M.D., M.M.Sc.
Treatment Decisions in Chemorefractory Follicular Lymphoma
Updates in Lymphoma From Recent Congresses
Jonathan W. Friedberg M.D., M.M.Sc.
Recent Advances in the Treatment of Lymphoma
Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.
Evaluating Next-Generation BTK Inhibitors
A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma
Navigating New Oral Treatment Algorithms in CLL
Managing Adverse Events With New Oral Therapies in CLL
Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL
Optimizing Outcomes and Managing Adverse Events in CLL
Vitolo U et al. Proc ASH 2011;Abstract 777.
What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,
What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,
Stephen Ansell, MD, PhD Mayo Clinic
Treatment guideline and algorithm for Advanced Stage Follicular and Nodal Marginal Zone* Lymphomas All patients should be considered for, and offered,
Fowler NH et al. Proc ASH 2011;Abstract 99.
Salles GA et al. Proc ASCO 2010;Abstract 8004.
Personalized Therapy in Relapsed or Refractory CLL
How to Select Therapy In Newly Diagnosed CLL
Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.
Follicular lymphoma Every patient should be treated at diagnosis
Non-Chemotherapy Combinations in CLL
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.
Assessing New Paradigms in CLL: MRD Negativity
FDA-Approved PI3K Inhibitors for CLL and FL
Proteasome Inhibitors and Patients
Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Managing CLL With BTK Inhibitors
Oral Treatment Strategies in CLL
Tailoring Therapy in the Newly Diagnosed Patient With CLL
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,
Treatment guideline and algorithm for Follicular and Nodal Marginal Zone* Lymphomas All patients should be considered for, and offered, NRCN/ MRC clinical.
Changing Paradigms in Relapsed/Refractory Indolent NHL
Treatment Initiation and Selection in Newly Diagnosed CLL
Presentation transcript:

Updates in Follicular Lymphoma

Learning Objectives

Follicular Lymphoma: Background and Demographics

WHO/REAL Grading of Follicular Lymphoma

Follicular Lymphoma International Prognostic Index (FLIPI)

FLIPI2

m7 FLIPI

Utility of PET and PET/CT in Follicular Lymphoma

NCCN Guidelines: First Line for Advanced Stage Follicular Lymphoma

Studies of Up-Front Treatment of Follicular Lymphoma

FOLL05 Study: Study Design and Outcomes

StiL Study: Bendamustine Plus Rituximab vs R-CHOP

BRIGHT Study: Bendamustine Plus Rituximab vs R-CHOP/R-CVP

PRIMA Study: Rituximab Maintenance vs Observation

FIT: 90Y-Ibritumomab Tiuxetan Consolidation vs Observation

The ZAR Study: Consolidation 90Y-Ibritumomab Tiuxetan vs Rituximab Maintenance

RESORT Study: Rituximab Maintenance vs Retreatment at Disease Progression

NCCN Guidelines: Relapsed FL

Phase 2 Study of R2 in Follicular Lymphoma: Study Design (MDACC)

R2 in Follicular Lymphoma: Outcomes

Alliance Trial: Rituximab Plus Lenalidomide in Follicular Lymphoma

Ibrutinib: Efficacy in FL Patients

Idelalisib: Phase 2 in Refractory iNHL

Obinutuzumab in CD20+ in Relapsed and/or Refractory FL

Venetoclax in Relapsed/Refractory FL

Personalized Treatment in Follicular Lymphoma

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.